ACSH s Dr. Josh Bloom is at it again, this time with an op-ed in Forbes. In this piece, Dr. Bloom describes two significant accomplishments of America s pharmaceutical industry within the past two decades: the development of effective anti-HIV drugs, and the recent approval of curative and tolerable treatments for hepatitis C. However, as Dr. Bloom points out, such innovations will be much less likely in the future.
ACSH s Dr. Josh Bloom is at it again, this time with an op-ed in Forbes. In this piece, Dr. Bloom describes two significant accomplishments of America s pharmaceutical industry within the past two decades: the development of effective anti-HIV drugs, and the recent approval of curative and tolerable treatments for hepatitis C. However, as Dr. Bloom points out, such innovations will be much less likely in the future. The industry has laid off massive numbers of its employees over the past decade, and shipped off much of its research staff to Asia, making it ill prepared for upcoming challenges, especially those posed by infectious disease.
You can read the full op-ed here.
